Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
29
MAQAF Quote, Financials, Valuation and Earnings
Last price:
$3.24
Seasonality move
:
0.53%
Day range:
$3.24 - $3.24
52-week range:
$2.69 - $3.60
Dividend yield:
0%
P/E ratio:
30.75x
P/S ratio:
47.18x
P/B ratio:
2.44x
Volume:
--
Avg. volume:
227
1-year change:
7.1%
Market cap:
$4.7B
Revenue:
$96.2M
EPS (TTM):
$0.11
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Atlas Arteria Ltd. has -- downside to fair value with a price target of -- per share.
MAQAF vs. S&P 500
-
Over the past 5 trading days, Atlas Arteria Ltd. has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atlas Arteria Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atlas Arteria Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Atlas Arteria Ltd. reported revenues of --.
Earnings Growth
-
Atlas Arteria Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Atlas Arteria Ltd. reported earnings per share of --.
Enterprise value:
7.8B
EV / Invested capital:
--
Price / LTM sales:
47.18x
EV / EBIT:
32.04x
EV / Revenue:
82.45x
PEG ratio (5yr expected):
1.00x
EV / Free cash flow:
--
Price / Operating cash flow:
9.77x
Enterprise value / EBITDA:
26.95x
Gross Profit (TTM):
$16.6M
Return On Assets:
4.15%
Net Income Margin (TTM):
--
Return On Equity:
5.38%
Return On Invested Capital:
4.21%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | $90.7M | $91.8M | -- | $93.3K | $214.3K | |
| Gross Profit | $90.7M | $86.4M | -- | $93.3K | $214.3K | |
| Operating Income | -$54.6M | $895.1K | -$32.1M | -$51.6M | $45.3M | |
| EBITDA | -$179.2M | -$8.9M | -$32.1M | -$51.6M | $45.3M | |
| Diluted EPS | -$0.60 | -$0.25 | $2.67 | -$0.10 | $0.01 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $152.3M | $142.1M | $118.9M | $182.1M | -- | |
| Total Assets | $3.9B | $3.5B | $5.5B | $5.3B | -- | |
| Current Liabilities | $76.8M | $76.4M | $80.6M | $80.5M | -- | |
| Total Liabilities | $1.2B | $1.2B | $1.2B | $1.2B | -- | |
| Total Equity | $2.6B | $2.3B | $4.3B | $4.1B | -- | |
| Total Debt | $1.2B | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-06-30 | 2012-06-30 | 2013-06-30 | 2012-06-30 | 2013-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -$3.4M | -$2.3M | -$63.8M | -$1.1M | -$65.9M | |
| Cash From Financing | -$58.5M | -$47M | -$41.6M | -$23.2M | -$10.7M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
MAQAF
Sector
Market Cap
$4.7B
$486.6M
Price % of 52-Week High
89.86%
79.89%
Dividend Yield
0%
0%
Shareholder Yield
--
1.54%
1-Year Price Total Return
7.1%
--
Beta (5-Year)
0.539
0.550
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-246.26%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$3.24
200-day SMA
Sell
Level
$3.40
Bollinger Bands (100)
Sell
Level
3.07 - 3.57
Chaikin Money Flow
Sell
Level
-3.2K
20-day SMA
Buy
Level
$3.23
Relative Strength Index (RSI14)
Buy
Level
57.83
ADX Line
Buy
Level
38.53
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$3.12
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
12.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7944)
Buy
CA Score
(Annual)
Level (0.7693)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.7227)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atlas Arteria Ltd. owns, operates, and develops toll roads globally. The firm's projects include toll roads, bridges, tunnels, and investment in entities in the same industry sector. It operates through the following segments: APRR, ADELAC, Warnow Tunnel, Chicago Skyway, and Dulles Greenway. The company was founded on December 16, 2009 and is headquartered in Melbourne, Australia.
Stock Forecast FAQ
In the current month, MAQAF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAQAF average analyst price target in the past 3 months is --.
-
Where Will Atlas Arteria Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atlas Arteria Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Atlas Arteria Ltd.?
Analysts are divided on their view about Atlas Arteria Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atlas Arteria Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Atlas Arteria Ltd.'s Price Target?
The price target for Atlas Arteria Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAQAF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atlas Arteria Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MAQAF?
You can purchase shares of Atlas Arteria Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atlas Arteria Ltd. shares.
-
What Is The Atlas Arteria Ltd. Share Price Today?
Atlas Arteria Ltd. was last trading at $3.24 per share. This represents the most recent stock quote for Atlas Arteria Ltd.. Yesterday, Atlas Arteria Ltd. closed at $3.24 per share.
-
How To Buy Atlas Arteria Ltd. Stock Online?
In order to purchase Atlas Arteria Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MAQAF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MAQAF
Sector
P/E ratio
30.75x
19.09x
PEG ratio
1.00x
0.18x
P/B ratio
2.44x
1.69x
Price / LTM sales
47.18x
0.85x
Growth Metrics
MAQAF
Sector
Revenue growth
--
5.02%
Earnings growth
--
5.88%
Revenue (5-year growth)
-3.76%
4.28%
Earnings forecast
--
$0.39
Profitability
MAQAF
Sector
Profitability FY 2024
$14.7M
$253.7M
Return on invested capital
4.21%
4.73%
Return on assets
4.15%
3.1%
Return on equity
5.38%
8.14%
Earnings Date
Last Earnings Date
Aug
27
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Nov
26
Balance Sheet
MAQAF
Sector
Total cash
$218.6M
$139.8M
Short term investments
--
$32.7M
Total assets
$5.1B
$1.4B
Long term debt
--
$51.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
